Navigation Links
Evonik Industries Selects OPX Biotechnologies for Joint Development of Bio-Based Chemicals
Date:5/14/2013

BOULDER, Colo. and ESSEN, Germany, May, 14 2013 /PRNewswire/ -- OPX Biotechnologies, Inc. (OPXBIO) and Evonik Industries AG today announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for OPXBIO to use its proprietary EDGE™ (Efficiency Directed Genome Engineering) technology to develop the bio-processes.

(Logo:  http://photos.prnewswire.com/prnh/20111108/CG01932LOGO)

"There's a growing market demand for more sustainable products and processes, and OPXBIO is an excellent partner to help us meet that demand because their technology can create high-value, bio-based chemicals quickly and cost-effectively," said Dr. Thomas Haas , Vice President Science-to-Business Center Biotechnology of Creavis, the strategic research and development unit of Evonik.

"Evonik is a leading global specialty chemicals company, and we're looking forward to helping them expand their portfolio of bio-based chemicals," said Charles R. (Chas) Eggert , OPXBIO president and CEO. "The bio-process we're developing has the potential to create economic and sustainable versions of products we use in our everyday lives." According to the agreement, OPXBIO will also be able to market bio-based products resulting from the Evonik collaboration.

About OPXBIO

OPX Biotechnologies (OPXBIO) is a leader in sustainably transforming the business of chemistry. As the "Good Chemistry" company, OPXBIO provides more sustainable value to customers by applying its proprietary EDGE ™ (Efficiency Directed Genome Engineering) technology to produce economic, bio-based chemicals that directly replace existing petroleum-based products. OPXBIO's EDGE is versatile and enables faster, more efficient development of bioprocesses using a variety of feedstocks. Founded in 2007, OPXBIO is financed by leading venture capital investors, and employs 65 people in Boulder, Colo.

For more information, visit www.opxbio.com and follow OPXBIO on Twitter.

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.


'/>"/>
SOURCE OPX Biotechnologies Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
2. Service Credit Union Selects DigitalPersona to Secure Access to Network and Applications
3. RedBrick Health Launches Open Integration and Partner Certification Program, Selects Fitbit, RunKeeper Among First to be "RedBrick Ready"
4. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
5. Crank Software Selects TREW Marketing for Embedded Industry Outreach
6. EU Commission selects Human Brain Project, with Israelis as partners
7. NSF selects OSU to lead project rejuvenating US research fleet
8. The Human Frontier Science Program selects new heads of start-up laboratories
9. Silex Technology Selects TREW Marketing for Branding and Marketing Strategy Following Co-Marketing Campaign with Freescale
10. Mount Sinai Selects Exemplar LIMS for Genomics Core Facility
11. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology: